

For Immediate Release



ASX Announcement

8 October, 2026
Melbourne, Australia

Update on U.S. Plasma Collection Network

CSL Limited (ASX:CSL; USOTC:CSLLY) today announces an expansion of its relationship with Haemonetics Corporation. CSL expects to have completed the rollout of Haemonetics' latest generation plasmapheresis platform across its U.S. plasma collection centres by the end of 2027.

CSL has entered into an agreement with Terumo BCT, Inc., provider of the Rika system currently used by CSL, to support a smooth transition between the providers.

The transition to the Haemonetics platform is one of several measures underway to further increase CSL's plasma collection network efficiency.

Authorised for lodgement by:

Fiona Mead
Company Secretary



Investor Relations

Michelle Rees
Head, Investor Relations
CSL Limited
P: +61 410 600 745
E: michelle.rees@csl.com.au



Media Relations

Brett Foley
Head, Media Relations
CSL Limited
P: +61 461 464 708
E: brett.foley@csl.com.au

CSL Limited | ABN 99 051 588 348 | 655 Elizabeth Street, Melbourne VIC 3000